Pfizer shares, PFE share prices on the Stock Exchange

Everything you need to know to stay updated on the financial market. Information, trend and graph in real time on the stock exchange quotations of the major stocks on world stock exchanges.

ISIN code: US7170811035
Sector: Healthcare technology
Industry: Pharmaceuticals: major

Pfizer shares are traded on the NYSE New York Stock Exchange under the ticker PFE.

View the stock's NYSE listing history

Company Description

Pfizer Inc. is a US pharmaceutical company headquartered in New York. It is the largest company in the world operating in the research, production and marketing of medicines. The strategic therapeutic areas for Pfizer are: anti-infective, central nervous system, treatment of pain and inflammation, urology, cardiovascular, endocrinology, ophthalmology and oncology.
Pfizer is also present in theveterinary area (Pfizer Animal Health).
The main business areas are: human pharmaceuticals with 91,8% of total turnover, veterinary with 5,4% of total turnover, and the remainder with 2,8% of total turnover. The top regions for profits are: USA 43,5% of profits, Europe 29,1%, Asia 16%, and other continents 11,4%.
For over a decade, Pfizer has been strategically engaged in a series of acquisitions of pharmaceutical companies in order to conquer increasingly significant shares of the world pharmaceutical market. Acquisitions that have resulted in the loss of jobs and stock value and numerous criticisms.
From 1986 Pfizer is listed on the Wall Street Stock Exchange. Pfizer was a component of the Dow Jones Industrial Average from 2004 to 2020, when it was replaced by Amgen. The change went into effect when trading began on August 31, 2020.

As of 2019, the company has around 88.300 employees.

Pfizer is responsible for various molecules including: Feldene (piroxicam), one of the first cornerstones of anti-inflammatory therapy in osteoarticular pathologies, Diflucan (fluconazole) the first oral antifungal for the treatment of opportunistic mycotic infections, Viagra (sildenafil), which continues to represent the symbol of the second sexual revolution. More recently Vfend (voriconazole), against fungal infections, Relpax (eletriptan), in the treatment of migraine, Sutent (sunitinib), which has changed the life expectancy of patients with renal cell carcinoma (MRCC) and cancer gastrointestinal tract stromal (GIST) and Champix (varenicline), born to help overcome smoking addiction.

In 2020, Pfizer is developing a COVID-19 virus vaccine. The development was carried out together with BionTech, who made the actual vaccine technology. On November 9, 2020 the drug was declared effective in 94% of cases tested and in the following two months it began to be distributed for administration to populations.

Its catchphrase is «Working together for a healthier world».

Economic and financial analysis

Pfizer is born in New York in 1849, when the cousins Charles Pfizer and Charles Erhardt, of German origin, began their trade in chemicals with the creation of Charles Pfizer and Company in a building in Brooklyn. Here they began to produce a pesticide called santonina. It was an instant hit. By 1910, sales were nearly $3 million, and Pfizer was firmly established as an expert in fermentation technology. These capabilities were applied to the mass production of penicillin during World War II, in response to calls from the US government.

In 1951 Branches begin to be established in Belgium, Brazil, Puerto Rico, Canada, Cuba and England and in 1952 the establishment of an agricultural sector began.

He then began his campaign of acquisitions in the pharmaceutical world with a view to conquering the world market. Over the years, Pfizer has made a series of acquisitions of pharmaceutical companies, aimed above all at obtaining the rights to strategic molecules for the development of its business.
In 1953 it acquired the JB Roerig & Co., a company specializing in dietary supplements. In 1971, it acquired the German drugmaker Heinrich Mack Illertissen.

In 1986 it entered the stock exchange.

In 2000 it acquired the Warner-Lambert (formerly Gödecke), German.
In 2003, Pfizer merged with pharmacy acquiring it for 60 million dollars. The merger was prompted in part by a desire to acquire full rights to a product, the selective COX-2 inhibitor Celebrex (celecoxib) previously marketed by Searle (acquired by Pharmacia) and Pfizer jointly in CoMarketing.

On January 26, 2009, Pfizer buys the rival Wyeth $68 billion in cash, including some loans from the big five Wall Street banks, totaling $22,5 billion. This deal makes Pfizer become like the largest pharmaceutical company in the world, with merger-generated revenues of more than $20 billion in cash annually. In May 2010, after the acquisition, a corporate restructuring plan was announced with the closure of production sites and personnel cuts that will affect 6.000 people worldwide

In 2009 he signed an agreement with with GSK for joint HIV research by creating a new company called ViiV Healthcare.

In April 2010 it acquired the Whitehall German OTC drug manufacturer.
On October 10, 2010, Pfizer bought the company for $3,6 billion King Pharmaceuticals, paying for it with a 40% premium on the previous Friday's closing share price. This acquisition was aimed at increasing revenues and reducing the impact of the imminent patent expiration of important drugs, but also to enter the lucrative painkillers market in which Kings Pharmauceticals was a leader in the US.

On October 18, 2010, Pfizer signed a strategic agreement with Biocon for the marketing of various formulations of insulins manufactured by the company. This operation cost a total of 350 million dollars.

On October 20, Pfizer acquired 40% of the Brazilian group Teuto Brasileiro S.A in order to potential its position on the Brazilian market.

On February 7, 2011, Pfizer purchased the Ferrosan, a company founded in 1920 with headquarters in Copenhagen and specialized in the production of dietary supplements.

In 2016, Pfizer Inc. was expected to merge with Allergan to create Ireland-based “Pfizer plc” in a deal reportedly worth $160 billion. The merger was canceled in April 2016, however, due to new US Treasury Department rules against tax inversions, a method of avoiding taxes by merging with a foreign company.

On December 19, 2018, Pfizer announced a joint merger of its consumer healthcare division with the British pharmaceutical giant GlaxoSmithKline; the British company will retain control of 68% of the shares.

Pfizer has been present in Italy since 1955, with a turnover in 2015 of over 1 billion euros and 3000 employees. The head office is at Rome where, in addition to the administrative offices, a business unit at the European level is housed. TO Milano there are international offices of Pharmacovigilance and Regulatory Strategy, a global oncology clinical development research group; as well as the Consumer Healthcare division. These structures are flanked by the three production plants of Ascoli Piceno, Aprilia (Latina) and Catania. The Pisticci plant, in the province of Matera, was sold in 2009 to Gnosis spa of Milan. Pfizer research in Italy is mainly oriented towards research in oncology and infectious diseases, in the central nervous system, in endocrinology and cardiovascular diseases. Currently Pfizer has developed 4 partnerships with the regions: Lombardy, Puglia, Lazio and Marche with respect to various health issues.

Pfizer research centers around the world are located in Groton (Connecticut USA), Sandwich (England), Tokyo (Japan), Amboise (France), La Jolla (California USA), Cambridge (Massachusetts USA), Ann Arbor (Michigan, USA ).

The shareholding structure of the Pfizer company is composed of:

Shareholder	Actions	Date reported	% output	Value
Vanguard Group, Inc. (The)	465.274.925	December 30 2021	8,29%	27.474.484.321
Blackrock Inc.	409.985.644	December 30 2021	7,30%	24.209.652.278
State Street Corporation	279.803.181	29 set 2021	4,99%	12.034.334.814
Capital World Investors	236.858.416	December 30 2021	4,22%	13.986.489.464
Wellington Management Group, LLP	221.419.680	December 30 2021	3,94%	13.074.832.104
Geode Capital Management, LLC	101.065.073	December 30 2021	1,80%	5.967.892.560
Northern Trust Corporation	67.992.185	December 30 2021	1,21%	4.014.938.524
Norges Bank Investment Management	60.296.992	December 30 2020	1,07%	2.219.532.275
Bank of America Corporation	57.448.235	December 30 2021	1,02%	3.392.318.276
Bank Of New York Mellon Corporation	54.674.452	December 30 2021	0,97%	3.228.526.390

Pfizer it has also often been at the center of numerous criticisms and controversies. Its quotations have often undergone ups and downs due to these controversies and its policy of expansion into the pharmaceutical world. Among the main controversies we recall that Pfizer in 1970 was forced to reimburse asbestos victims of Quigley, its subsidiary. In 1994 it was ordered to reimburse victims of defective heart valves of its subsidiary, Bjork-Shiley heart valve. In 1996 you are accused in Nigeria, when during a serious epidemic in the city of Kano, several children were subjected to unauthorized human experimentation (Kano litigation). In 2005 its CEO McKinnell is named as one of the biggest offenders of human rights: Most Wanted Corporate Human Rights Violators 2005. During the five years under Mckinnell (2002-2007) the stock market value of the company had a loss of about 40%.

Even in Italy Pfizer has often been accused and has dismissed research centers and several hundred workers of the acquired companies.

Pfizer revenue in 2020 was $178,983 billion with profit of $65,495 billion.
Currently the listing is at $38,52 to action.